Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2